Revvity (RVTY) said Thursday it has signed a new agreement with Genomics England to further collaborate on the Generation Study, a national initiative to screen up to 100,000 newborns for more than 200 rare genetic disorders.
Under the new contract, Revvity said it will also provide DNA sequencing services to help screen newborns for rare genetic conditions, adding to its previous DNA extraction services.
The firm said it will now be able to provide an end-to-end solution with a localized lab facility to advance the screening process.
Price: 107.11, Change: -2.81, Percent Change: -2.56
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.